[Downloaded free from http://www.ijo.in on Wednesday, November 29, 2017, IP: 95.10.27.170]
Letters to the Editor Subconjunctival sustained‑release dexamethasone implant as an adjunct to trabeculectomy for primary open angle glaucoma Sir, In the present study, we described the first case series of intraoperative positioning of subconjunctival dexamethasone implant as adjunctive antiscarring agent in patients undergone trabeculectomy for primary open angle glaucoma (POAG). The rationale of subconjunctival dexamethasone implant injection was to reduce the postsurgical overscarring at the site of the bleb, by limiting the first acute inflammatory reaction that represents the primum movens for conjunctival healing. Three eyes of three consecutive patients (three female) with a mean age of 61 ± 14.5 years taking a maximum tolerated dose of intraocular pressure (IOP)‑lowering medication for POAG with a recorded IOP of ≥18 mmHg, glaucomatous damage on visual field and underwent trabeculectomy: All patients underwent a limbus‑based conjunctival flap with one circumferential and one radial incision, antimetabolite sponge application, and scleral rectangular flap which was sutured with 10‑0 nylon suture, sclerostomy with punch a peripheral iridectomy. Before the conjunctival suture with 9‑0 vicryl was performed, a subconjunctival apposition without fixation of 0.7 mg sustained‑release dexamethasone implant (Ozurdex, Allergan, Inc., Irvine, USA) was obtained. The implant was softly leaned on the sclera posterior to the flap. After 7 days, 1 month, and 2 months, the implant seemed to fragment reducing progressively its dimensions and was no more detectable after 2 months in all eyes [Fig. 1].
a
b
After 2 months, IOP not quite significantly (P = 0.056, nonparametric Mann–Whitney U‑test) decreased from 19.3 ± 2.3 mmHg (median: 18, interquartile range [IQR]: 4) at baseline to 15.7 ± 0.6 mmHg (median: 16, IQR: 1) without any glaucoma medication. In all eyes, IOP was ≤16 mmHg (range: 15–16). After 2 months in all the cases, conjunctival scarring at the site of the filtering bleb was not observed. No ocular adverse event or postoperative complications were observed. Corticosteroids have long been used as inflammation modulators of posttrabeculectomy conjunctival healing with significantly success rates, since they act on vascular permeability, as well as white blood cell chemotaxis and function.[1] First evidence of steroids effects in glaucoma surgery came from Starita et al.,[2,3] who investigated the effects of topical and systemic steroids in a randomized prospective trial. They found that topical steroids significantly improved trabeculectomy outcome as compared to the group without steroids at 5 and 10 years. There are studies about the intraoperative subconjunctival injection of triamcinolone acetonide (TA) after bleb‑forming filtration surgery.[4] TA injections appeared to be safe in both studies, with no significant adverse events, even if results of a randomized controlled trial about long‑term clinical benefits in patients receiving intrableb TA against whom receiving topical steroids only, have not been published yet. The rationale of intraoperative subconjunctival corticosteroid injection was to find a more direct, sustained, and convenient mode of steroid delivery in the operated patients; moreover, the bulk of injected TA would also serve as a barrier between the inflamed conjunctiva and sclera, to avoid adherence in between. In this view, Ozurdex implant would be even more effective than TA, lasting longer and interposing a bigger volume in the conjunctival layers. Subconjunctival implant appears to be well tolerated by operated eyes. However, use of Ozurdex has been associated with several adverse events including posterior subcapsular cataract and a higher risk of eye infections;[5] reasonably, the most threatening glaucoma surgery success is eye pressure increase that may need supplementary IOP lowering medical therapy after trabeculectomy. Effective success of surgery should therefore be taken only several weeks after the operation, when the insert is completely reabsorbed. Limitations of this study were the small sample size and the absence of a control group.
c
d
Figure 1: Patient with primary open angle glaucoma undergone trabeculectomy and subconjunctival apposition of 0.7 mg sustained‑release dexamethasone implant at day 1 (a), day 7 (b), month 1 (c), and month 2 (d). The implant seemed to fragment reducing progressively its dimensions and was no more detectable after 2 months
The data of this pilot study showed that no serious side effects were noted, subconjunctival Ozurdex was well tolerated and that a controlled study is required to establish the efficacy of this easy to perform the technique. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
© 2016 Indian Journal of Ophthalmology | Published by Wolters Kluwer - Medknow
[Downloaded free from http://www.ijo.in on Wednesday, November 29, 2017, IP: 95.10.27.170]
252
Indian Journal of Ophthalmology
Vol. 64 No. 3
Claudio Furino, Francesco Boscia1, Maria Vittoria Cicinelli, Alessandra Sborgia, Giovanni Alessio
4. Giangiacomo J, Dueker DK, Adelstein E. The effect of preoperative subconjunctival triamcinolone administration on glaucoma filtration. I. Trabeculectomy following subconjunctival triamcinolone. Arch Ophthalmol 1986;104:838‑41.
Department of Ophthalmology, University of Bari, Bari, 1 Department of Ophthalmology, Eye Clinic, University of Sassari, Sassari, Italy
5. London NJ, Chiang A, Haller JA. The dexamethasone drug delivery system: Indications and evidence. Adv Ther 2011;28:351‑66.
Correspondence to: Dr. Claudio Furino, Department of Ophthalmology, University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy. E‑mail:
[email protected]
This is an open access article distributed under the terms of the Creative Commons Attribution‑NonCommercial‑ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non‑commercially, as long as the author is credited and the new creations are licensed under the identical terms.
References 1. Nuzzi R, Vercelli A, Finazzo C, Cracco C. Conjunctiva and subconjunctival tissue in primary open‑angle glaucoma after long‑term topical treatment: An immunohistochemical and ultrastructural study. Graefes Arch Clin Exp Ophthalmol 1995;233:154‑62. 2. Starita RJ, Fellman RL, Spaeth GL, Poryzees EM, Greenidge KC, Traverso CE. Short‑ and long‑term effects of postoperative c o r t i c o s t e r o i d s o n t r a b e c u l e c t o m y. O p h t h a l m o l o g y 1985;92:938‑46.
Access this article online Quick Response Code:
Website: www.ijo.in DOI: 10.4103/0301-4738.181735 PMID: ***
3. Araujo SV, Spaeth GL, Roth SM, Starita RJ. A ten‑year follow‑up on a prospective, randomized trial of postoperative corticosteroids after trabeculectomy. Ophthalmology 1995;102:1753‑9.
Cite this article as: Furino C, Boscia F, Cicinelli MV, Sborgia A, Alessio G. Subconjunctival sustained-release dexamethasone implant as an adjunct to trabeculectomy for primary open angle glaucoma. Indian J Ophthalmol 2016;64:251-2.
Comments on temporary resolution of foveal schisis following vitrectomy with silicon oil tamponade in X‑linked retinoschisis with retinal detachment
published earlier,[2] surgery for foveal schisis alone hence may not always be fruitful.
Sir, Goel and Ghosh present a very interesting case in their report entitled, “Temporary resolution of foveal schisis following vitrectomy with silicon oil tamponade in X‑linked retinoschisis with retinal detachment.” [1] The authors document with the help of optical coherence tomography, temporary resolution of foveal schisis in a case operated for retinal detachment with X‑linked retinoschisis, that recurred after silicone oil removal. The case not only provides an insight into pathology of the inherited disorder but also underlines the irreversible visual loss that may be associated with foveal schisis. Visual acuity had improved to 20/120 at the time when foveal schisis had temporarily resolved due to oil tamponade, but after its recurrence following oil removal, the visual acuity remained similar, 20/80, instead of decreasing that one may expect. Therefore, morphological alignment of the middle retinal layers did not contribute to visual acuity which had been lost permanently. Although good results with surgery have been
Another valuable conclusion that one may draw from this unique case is that the best time to perform internal limiting membrane (ILM) peel in such cases of retinal detachment would be during oil removal rather than during vitrectomy itself. Macula at that time would be more resistant to inadvertent damage due to manual traction. The authors too mention the controversy surrounding ideal treatment of X‑linked foveal schisis and the risk of macular complication during ILM peel in patients with foveal schisis. We keenly await the authors’ response. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
Brijesh Takkar, Shorya V Azad Dr. RP Center for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India Correspondence to: Dr. Brijesh Takkar, Dr. RP Center for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India. E‑mail:
[email protected]
